Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Interest & Investment Income (2017 - 2022)

Kiniksa Pharmaceuticals International filings provide 2 years of Interest & Investment Income readings, the most recent being $322000.0 for Q3 2022.

  • On a quarterly basis, Interest & Investment Income rose 6340.0% to $322000.0 in Q3 2022 year-over-year; TTM through Sep 2022 was $536000.0, a N/A change, with the full-year FY2021 number at $97000.0, down 91.45% from a year prior.
  • Interest & Investment Income hit $322000.0 in Q3 2022 for Kiniksa Pharmaceuticals International, up from $103000.0 in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $322000.0 in Q3 2022 to a low of $5000.0 in Q3 2021.